Articles Vol. 65 No. Tiếng Anh 12/12/2024

3. STUDY OF PROSTAGLANDIN E2 LEVEL IN PATIENTS WITH POLYPS AND COLORECTAL CANCER

Ho Van Son1, Le Duy Thanh2, Nguyen Nguyet Quynh Mai1
1 Military Hospital 175
2 108 Central Military Hospital
DOI: 10.52163/yhc.v65i13.1724
21 Views
16 Downloads
Keywords
Prostaglandin E2 Colorectal cancer colorectal polyps
Abstract

Objectives: To describe the characteristics of age, sex; histopathology; some paraclinical features and to evaluate the concentration of Prostaglandin E2 in two groups of patients with polyps and colorectal cancer (CRC).

Methods: Cross-sectional descriptive study on 308 patients: including 149 CRC patients and 109 patients with colorectal polyps diagnosed by cytology or histopathology, 50 healthy individuals; who were examined and treated at Military Hospital 175.

Results: The mean age in the CRC group was 59,64 ± 11,66; in the colorectal polyps group was 58,45±9,65; in the healthy group was 57,32±8,17; there was no difference in age between the study groups. The incidence is higher in men than in women, and this difference is statistically significant (p=0,0061). Adenocarcinoma is dominant in CRC patients (77,85%); for polyps, adenomas are dominant (83,49%). The mean PGE2 concentration in CRC patients was 7,86±2,8 pg/ml; in polyp patients was 5,29±1,3 pg/ml; in healthy people it was 2,78±0,5 pg/ml.

Conclusions: There was no difference in the concentration of PGE2 in the polyp and CRC groups (p>0,05). However, there was a significant difference in PGE2 levels in the two groups of cancer and colorectal polyps compared to healthy individuals (p< 0,05 (0,0021)).

References
[1]
Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2014. Ann Oncol. Aug 2014;25(8):1650-6. Google Scholar
[2]
Jemal A, Ward EM, Johnson CJ, et al. Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival. J Natl Cancer Inst. Sep 1 2017;109(9) Google Scholar
[3]
Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. Jul 2020;70(4):313. Google Scholar
[4]
Marmol I, Sanchez-de-Diego C, Pradilla Dieste A, Cerrada E, Rodriguez Yoldi MJ. Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer. Int J Mol Sci. Jan 19 2017;18(1) Google Scholar
[5]
Inaba T, Sano H, Kawahito Y, et al. Induction of cyclooxygenase-2 in monocyte/macrophage by mucins secreted from colon cancer cells. Proc Google Scholar
[6]
Natl Acad Sci U S A. Mar 4 2003;100(5):2736-41. Google Scholar
[7]
Wang X, Yao B, Wang Y, et al. Macrophage Cyclooxygenase-2 Protects Against Development of Diabetic Nephropathy. Diabetes. Feb 2017;66(2):494-504. Google Scholar
[8]
Ylostalo JH, Bartosh TJ, Coble K, Prockop DJ. Human mesenchymal stem/stromal cells cultured as spheroids are self-activated to produce prostaglandin E2 that directs stimulated macrophages into an anti-inflammatory phenotype. Stem Cells. Oct 2012;30(10):2283-96. Google Scholar
[9]
Eruslanov E, Kaliberov S, Daurkin I, et al. Altered expression of 15-hydroxyprostaglandin dehydrogenase in tumor-infiltrated CD11b myeloid cells: a mechanism for immune evasion in cancer. J Immunol. Jun 15 2009;182(12):7548-57. Google Scholar
[10]
Wu WK, Llewellyn OP, Bates DO, Nicholson LB, Dick AD. IL-10 regulation of macrophage VEGF production is dependent on macrophage polarisation and hypoxia. Immunobiology. SepOct 2010;215(9-10):796-803. Google Scholar
[11]
Ratcliffe MJ, Walding A, Shelton PA, Flaherty A, Dougall IG. Activation of E-prostanoid4 and E-prostanoid2 receptors inhibits TNF-alpha release from human alveolar macrophages. Eur Respir J. May 2007;29(5):986-94. Google Scholar